The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders.
Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.
Data from a collaborative study between the University Hospital Basel (UHB) and MindMed supports the clinical development of MindMed’s proprietary MM-120 product candidate – a pharmacologically...
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.
Launched by Subreddit r/HPPD in partnership with the scientific research app Quantified Citizen, the retrospective, observational study aims to investigate possible links between Hallucinogen Persisting Perception...
Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...
